Status:
COMPLETED
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epider...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients must have had NSCLC.
- Patients must have received erlotinib (single-agent) for six months or longer for NSCLC in the second/third line setting or as maintenance therapy.
- Patients must have tissue available for EGFR-mutation status testing (if not previously performed) or EGFR-mutation status test results available.
- Patients must have tissue available for exploratory genetic analysis.
- Patients must have all clinical information, treatment response data and outcomes data available for review.
- Patients must be deceased.
Exclusion
Key Trial Info
Start Date :
October 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01522833
Start Date
October 1 2012
End Date
February 1 2015
Last Update
March 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tennessee Oncology, PLLC
Nashville, Tennessee, United States, 37023